- Company/Commercial (9)
- Corporate (8)
- Healthcare (7)
- Intellectual Property (4)
- Litigation / Dispute Resolution (4)
- Regulatory and compliance (4)
- Banking / Finance (2)
- Construction (2)
- Employment (2)
- Media/Entertainment/Sport (2)
- Tax (2)
- Agriculture (1)
- Crime (1)
- Environment (1)
- Financial services (1)
- Funds (1)
- Information Technology (1)
- Licensing/Gaming/Betting (1)
- Professional Indemnity/Negligence (1)
- Public Sector/Local Authority (1)
- Real Estate (1)
- Telecoms (1)
- Transport (Including aviation and shipping) (1)
Sort By: Newest first | Oldest first
The M&A team at Wierzbowski Eversheds has advised Perma-Fix Medical on its reverse merger with CEE Opportunity Partners Poland.
Eversheds has strengthened its international intellectual property (IP) and life sciences offering with the hire of partner Gunther Meyer.
Ben Jones has commented on news that AbbVie is reconsidering its $54bn takeover of UK drug maker Shire in light of the recent crackdown on tax inversion deals.
Eversheds has advised the Cell Therapy Catapult on a partnership with UCL Business (UCLB) and Imperial Innovations.
Jonathan Brook has joined Eversheds as a partner in the law firm’s London litigation team.
Chambers & Partners has published the latest Chambers Europe 2014 guide. Wierzbowski Eversheds has been recommended in numerous fields of law.
Parmjit Singh, head of the India business group at Eversheds, has commented following Sun Pharmaceuticals’ acquisition of Ranbaxy.
Eversheds partner Richard Lewis has commented on Sun Pharmaceuticals’ acquisition of Ranbaxy.
Eversheds’ Madrid office has successfully represented pharmaceutical company MSD Spain in a landmark patent dispute.
As test results from a public laboratory in West Yorkshire find more additives in food products, Eversheds’ health and safety partner David Young considers the consequences.
The Hong Kong office of Eversheds has advised BOCI Asia in connection with the HKD1.09bn initial public offering (IPO) of Consun Pharmaceutical Group.
Eversheds has advised Milan-based Recordati Spa on the acquisition of 67 per cent of shares in Tunisian pharmaceutical company Opalia Pharma.
Simon Crossley of Eversheds has commented in response to calls from the pharmaceutical industry that the number of medicines being blocked from the UK market by NICE is too high.
Eversheds has been appointed as legal adviser to the Cell Therapy Catapult, a UK centre of excellence in cell therapy, following a competitive pitch process.
Eversheds Ireland has played a key role in the takeover by Endo Health Solutions of Paladin Labs Europe for approximately £1.1bn.
Simon Crossley from Eversheds believes the deal should be a good outcome for industry and government.
Eversheds has commented on proposed new laws governing medical devices being debated in the EU parliament.